Revive Therapeutics Ltd Stock Price, News & Analysis

Revive Therapeutics (OTCQB: RVVTF) is nearing completion of a crucial study evaluating Bucillamine as a nerve agent countermeasure in partnership with Defence R&D Canada (DRDC). The study is set to conclude by September 2025, with potential Health Canada approval for strategic stockpiling by 2026.

Bucillamine, a thiol-based drug with proven safety profile, works by replenishing glutathione to protect the brain and organs from toxic exposures. The company aims to expand its applications to include traumatic brain injury (TBI) and viral infections. The successful development could position Revive for significant government stockpiling contracts with Canada and its "Five Eyes" intelligence partners.

Revive Therapeutics (RVVTF) announces advancement in developing a next-generation lyophilized formulation of Bucillamine in collaboration with the University of Waterloo. The company is positioning New Bucillamine to target public health emergencies, including pandemic influenza and emerging infectious diseases. Bucillamine, which already holds FDA Orphan Drug Designation for ischemia-reperfusion injury in organ transplantation since 2022, shows promise in enhancing solid tumor treatments. The company is working with Defence R&D Canada to evaluate Bucillamine for nerve agent exposure, with results expected by June 2025. Clinical trials could begin in H2 2025, pending positive results. Revive is pursuing various FDA incentives and exploring partnerships to accelerate development and commercialization.

Revive Therapeutics (RVVTF) has provided an update on its research study of Bucillamine as a potential treatment for nerve agent exposure, conducted in partnership with Defence R&D Canada – Suffield Research Centre (DRDC). The study is scheduled to conclude by June 2025, focusing on GABA receptor antibodies and data confirmation. Positive results could lead to human clinical trials in the second half of 2025, seeking FDA and Health Canada approvals for nerve agent and organophosphate pesticide poisoning treatment.

Bucillamine, which is a more potent antioxidant than n-acetylcysteine (NAC), shows potential in protecting GABA(A) receptors and improving anticonvulsant therapies' effectiveness while reducing bleeding risks associated with NAC. The research also explores Bucillamine's applications in traumatic brain injury and viral infections.

Revive Therapeutics (OTCQB: RVVTF) has announced a proposed shares for debt transaction to settle $150,000 in payables to arm's length parties through the issuance of 6,000,000 common shares at $0.025 per share. The issue price is calculated based on the 20-day VWAP of shares traded on the CSE.

The company aims to preserve cash for ongoing operations through this debt settlement. The transaction is subject to customary closing conditions, with shares to be issued having a four-month and one-day hold period from issuance date.

Revive Therapeutics (OTCQB: RVVTF) has been approached by a prominent U.S. University Cancer Institute researcher to investigate Bucillamine's potential in cancer treatment, specifically for enhancing anti-tumor effects in advanced solid tumors. The research would be supported by NIH and other government funding.

The investigation builds on existing partnerships, including one with Defence R&D Canada – Suffield Research Centre, which is evaluating Bucillamine for nerve agent exposure treatment. The cancer research focuses on Bucillamine's role as a thiol donor that could neutralize reactive oxygen species and replenish reduced glutathione in the tumor microenvironment (TME), potentially amplifying antitumor effects.

This approach aims to address challenges in nucleic acid-based therapies, particularly regarding drug delivery and stability in the TME, which is characterized by low oxygen levels and elevated reduced glutathione.

Revive Therapeutics (RVVTF) has acquired DiagnaMed's molecular hydrogen intellectual property through an asset purchase agreement dated March 31, 2025. The acquisition, valued at $50,000, will be satisfied through the issuance of one million common shares at $0.05 per share.

The acquired assets include a provisional patent application for pharmaceutical-based methods using molecular hydrogen to treat neurological and mental health disorders, including Dementia, Parkinson's disease, Traumatic brain injury, Depression, Anxiety, and Post-traumatic stress disorder. Additionally, the acquisition includes research activities and an FDA Orphan Drug Designation (ODD) for molecular hydrogen in treating ALS.

ALS affects approximately 50,000 people in the U.S. and Europe, with over 5,000 new cases diagnosed annually. The disease has a life expectancy of two to six years after diagnosis, with no known cure currently available.

Revive Therapeutics (OTCQB: RVVTF) held its annual shareholder meeting on March 18, 2025, where several key decisions were made. Shareholders elected five board members, including CEO Michael Frank and four independent directors: Joshua Herman, Andrew Lindzon, William Jackson, and Christian Scovenna.

The meeting also resulted in the approval of Horizon Assurance LLP as the company's auditor, authorization for directors to set auditor remuneration, and continuation of the company's 10% rolling incentive stock option plan. Notably, following shareholder feedback, the Board decided not to proceed with a proposed amendment to consolidate outstanding Common Shares.

Revive Therapeutics (RVVTF) has entered into a non-binding letter of intent to acquire DiagnaMed Holdings Corp.'s intellectual property related to molecular hydrogen treatments for neurological and mental health disorders. The acquisition includes:

• A provisional patent application for pharmaceutical-based methods and compositions for molecular hydrogen treatments
• Research work and FDA Orphan Drug Designation for molecular hydrogen in treating ALS

The acquisition is expected to close by March 31, 2025. The company aims to develop treatments for conditions including Dementia, Parkinson's, Traumatic brain injury, Depression, Anxiety, and PTSD. Additionally, Revive secured a $65,000 loan at 8% interest, maturing February 19, 2026, for working capital needs.

Revive Therapeutics (OTCQB: RVVTF) has provided an update on its R&D focus for Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties. The company is pursuing two main programs:

1. Medical Countermeasures: In partnership with Defence R&D Canada, evaluating Bucillamine as a treatment for nerve agent exposure. The research study is expected to complete in February 2025.

2. Infectious Diseases: Targeting Long COVID as initial indication. Previous Phase 3 trial data showed Bucillamine demonstrated 29.1% improvement over placebo in time to normal oxygen saturation for patients with oxygen saturation <96% at baseline. The company plans to submit a Phase 2 study protocol to FDA by Q1-2025, with expected approval in Q2-2025.

Additionally, the company disclosed a consent judgment regarding an arbitration award of €301,806.5 and USD$160,800 plus costs, with enforcement delayed until May 22, 2025.